Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor
Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor
复制标题
DOI：
10.3748/wjg.15.5867
复制
发表时间：
2009-12-14
影响因子：
4.3
通讯作者：
Baum, Richard P.
中科院分区：
文献类型：
--
作者：
Kaemmerer, Daniel;Prasad, Vikas;Baum, Richard P.
胰腺内分泌肿瘤是罕见的，但其中最常见的神经内分泌肿瘤的腹部。在诊断他们中的许多人已经先进和难以treat.We报告最初无法手术的恶性胰腺内分泌肿瘤在33岁的妇女，谁接受新辅助肽受体放射性核素治疗（PRRT）作为一线治疗。这导致了肿瘤的显著降级，并允许其随后的完全手术切除。随访18个月，完全缓解。这是第一次报告新辅助PRRT在神经内分泌肿瘤，随后成功地完全切除。(C)2009 WJG出版社和百世登。All rights reserved.
Pancreatic endocrine tumors are rare but are among the most common neuroendocrine neoplasms of the abdomen. At diagnosis many of them are already advanced and difficult to treat. We report on an initially inoperable malignant pancreatic endocrine tumor in a 33-year-old woman, who received neoadjuvant peptide receptor radionuclide therapy (PRRT) as first-line treatment. This resulted in a significant downstaging of the tumor and allowed its subsequent complete surgical removal. Follow-up for eighteen months revealed a complete remission. This is the first report on neoadjuvant PRRT in a neuroendocrine neoplasm with subsequent successful complete resection. (C) 2009 The WJG Press and Baishideng. All rights reserved.